NCT02157883 2025-11-19Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)AstraZenecaPhase 1 Completed39 enrolled 18 charts
NCT04721015 2025-07-03Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsAbbViePhase 1 Active not recruiting81 enrolled
NCT04862780 2025-02-10(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCBlueprint Medicines CorporationPhase 1 Terminated177 enrolled
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT05153408 2023-06-18(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCBlueprint Medicines CorporationPhase 1 Terminated20 enrolled
NCT03255083 2022-01-19DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerDaiichi SankyoPhase 1 Terminated13 enrolled 19 charts